行情

CRBP

CRBP

Corbus Pharms
NASDAQ

实时行情|Nasdaq Last Sale

4.440
+0.070
+1.60%
已收盘, 17:52 11/19 EST
开盘
4.380
昨收
4.370
最高
4.524
最低
4.360
成交量
55.98万
成交额
--
52周最高
9.11
52周最低
4.180
市值
2.87亿
市盈率(TTM)
-4.3624
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRBP 新闻

  • 沪指低开低走 纽约联储主席称美经济面临下行风险
  • 新浪财经.2小时前
  • 击败亚马逊微软 谷歌赢得沃达丰数据服务大单
  • TechWeb.5小时前
  • 道明证券:"巨大风险事件"使风险对冲成2020年的佳选
  • 新浪财经综合.5小时前
  • 港交所:推出阿里巴巴集团控股有限公司股票期权
  • 新浪科技.6小时前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

CRBP 简况

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
展开

Webull提供Corbus Pharmaceuticals Holdings Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。